Back to Authors

Tefferi, Ayalew

https://orcid.org/0000-0003-4605-3821

A5016216479 | I1330342723

Mayo Clinic

Citations 935

Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience

Blood Advances | December 7, 2022 | Volume: 7 | Issue: 8 | Pages: 1351-1355

10.1182/bloodadvances.2022007937 | PMID 36477202

Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3233-3234

10.1182/blood-2022-167967

Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3235-3236

10.1182/blood-2022-169319

Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3945-3946

10.1182/blood-2022-160179

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6940-6941

10.1182/blood-2022-163518

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9675-9676

10.1182/blood-2022-163485

Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12353-12354

10.1182/blood-2022-155561

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6872-6873

10.1182/blood-2022-167720

Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9602-9603

10.1182/blood-2022-167405

TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9798-9799

10.1182/blood-2022-165859